Metabolic markers in blood can separate prostate cancer from benign prostatic hyperplasia

BACKGROUND: An individualised risk-stratified screening for prostate cancer (PCa) would select the patients who will benefit from further investigations as well as therapy. Current detection methods suffer from low sensitivity and specificity, especially for separating PCa from benign prostatic cond...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Br J Cancer
Hauptverfasser: Giskeødegård, Guro F, Hansen, Ailin Falkmo, Bertilsson, Helena, Gonzalez, Susana Villa, Kristiansen, Kåre Andre, Bruheim, Per, Mjøs, Svein A, Angelsen, Anders, Bathen, Tone Frost, Tessem, May-Britt
Format: Artigo
Sprache:Inglês
Veröffentlicht: Nature Publishing Group 2015
Schlagworte:
Molecular Diagnostics
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4702000/
https://ncbi.nlm.nih.gov/pubmed/26633561
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2015.411
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge